MorphoSys AG (MOR)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in MorphoSys AG, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

MorphoSys AG (MOR) has returned 0.00% so far this year and 0.00% over the past 12 months.

Based on dividend-adjusted daily data since Apr 19, 2018, MOR's average daily return is +0.04%, while the average monthly return is +0.59%. At this rate, your investment would double in approximately 9.8 years.

Historically, 36% of months were positive and 64% were negative. The best month was Feb 2024 with a return of +67.5%, while the worst month was Jul 2021 at -27.7%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 8 months.

On a daily basis, MOR closed higher 39% of trading days. The best single day was Feb 5, 2024 with a return of +56.0%, while the worst single day was Nov 14, 2022 at -27.8%.

MorphoSys AG has an annualized alpha of -1.49%, beta of 0.79, and R² of 0.09 versus S&P 500 Index. Calculated based on daily prices since April 20, 2018.

• This stock participated in 139.77% of S&P 500 Index downside but only 80.21% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.09 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

The table below present risk-adjusted performance metrics for MorphoSys AG (MOR) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the MorphoSys AG. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the MorphoSys AG was 91.41%, occurring on Dec 27, 2022. The portfolio has not yet recovered.

The current MorphoSys AG drawdown is 49.25%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of MorphoSys AG over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how MorphoSys AG is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.